Detection ofChlamydia trachomatisandNeisseria gonorrhoeaewith the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Qxand GC Qxamplified DNA and Aptima AC2 assays

Nye, Melinda B.; Osiecki, J; Lewinski, Michael A.; Liesenfeld, Oliver; Young, Stephen; Taylor, Stephanie N.; Lillis, Rebecca A.; Body, Barbara A.; Eisenhut, Carol; Hook, Edward W.; Pol, Barbara Van Der

doi:10.1136/sextrans-2018-053545

Cited by 13 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial C. trachomatis screening was performed with either Roche Cobas Amplicor or Roche Cobas 4800 (Roche Diagnostics, Basel, Switzerland), which are both very sensitive commercial assays (lower detection limit 40 bacteria/ml 21 , sensitivity 91.2%-98%, [21][22][23] specificity ≥98.8%.) 22 23 The C. trachomatis load was quantified in positive samples by inhouse quantitative PCR (qPCR) targeting the chromosomal OmpA-gene.…”

Section: Trachomatis Load Quantificationmentioning

confidence: 99%

Genital and analChlamydia trachomatisbacterial load in concurrently infected women: a cross-sectional study

et al. 2019

View full text Add to dashboard Cite

ObjectivesMost international STI guidelines recommend Chlamydia trachomatis anorectal testing in women after self-reported sexual exposure or symptoms in women. However, it has been shown that the prevalence of anorectal C. trachomatis is as high (7%–17 %) in women who do not report anorectal intercourse (AI) as in women who do. This study assessed the correlation between the genital and anorectal C. trachomatis load in concurrently infected women for increased microbiological insight.MethodsA convenience sample of 105 women with a concurrent (genital and anorectal) C. trachomatis infection was included from the STI clinic in South Limburg, the Netherlands. Women provided self-collected vaginal and anorectal swabs. The C. trachomatis load was quantified with qPCR and the human cell load was assessed to ensure sample adequacy. Genital and anorectal C. trachomatis loads were divided into tertiles for comparison. The χ2 test and linear regression were used to compare genital and anorectal C. trachomatis loads and identify determinants associated with load.ResultsThe overall median C. trachomatis load was higher in genital (median 5.3 log10C. trachomatis/ml) than anorectal samples (median 3.4, p ≤ 0.001), but both loads were within the same range. The genital and anal load categories were not related within one woman (p = 0.99), both in women with and without AI. The anorectal C. trachomatis load was in the same or higher load category than the genital load in 56% of women without AI, and 79% of women with AI.ConclusionsAlthough no cut-off for clinical relevance is known, an anorectal C. trachomatis load in the same or higher load category than the genital C. trachomatis load is likely to be clinically relevant. Other measurements should also be taken into account, such as leucocytes or bacterial viability to distinguish infection from contamination or exposure.

show abstract

Section: Trachomatis Load Quantificationmentioning

confidence: 99%

Genital and analChlamydia trachomatisbacterial load in concurrently infected women: a cross-sectional study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…These are the nucleic acid amplification tests (NAATs) based on a polymerase chain reaction (PCR), namely Roche AMPLICOR and COBAS AMPLICOR 2 : one based on strand displacement amplification (BD ProbeTec ET System; Becton Dickinson, Sparks, MD) 3 and one based on transcription-mediated amplification (TMA): APTIMA Combo 2 (Hologic Inc. San Diego, CA). 4 The Cobas CT/NG v2.0 test (Roche Molecular Systems, Branchburg, NJ) 5 behaves comparably to the others mentioned, as does the Abbott m2000 Real Time CT/NG assay (Abbott Molecular; Des Plaines, IL). 6 The GeneXpert CT/NG assay (Cepheid, Sunnyvale, CA), with similar performance to the aforementioned NAATs produces a result within 1.5 h. All these methods offer excellent sensitivity, usually well above 90%, while maintaining very high specificity.…”

Section: Neisseria Gonorrhoeaementioning

confidence: 91%

Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges

2020

View full text Add to dashboard Cite

Promptly and accurately diagnosing genital-tract infections is key to instituting appropriate treatment and control of sexually transmitted infections (STIs). Ano-genital tract testing for STIs in the last two decades has not entirely moved away from insensitive methods but it is now at least dominated by highly sensitive molecular methods. These tests can be ordered through the internet for use at home, with self-taken specimens then returned, usually by post, to a clinic or laboratory for testing. The increasing ease of access of the public to this situation, together with increasing on-line health-seeking behaviour, has resulted in a gap between commercial and NHS management pathways for STIs. Crucially, patients who order multiplex test kits on-line for use at home, and other non-specialists, may not realize that it is worthwhile testing only for Neisseria gonorrhoeae, Chlamydia trachomatis, and possibly Trichomonas vaginalis, and Mycoplasma genitalium if the person is symptomatic or their current partner is infected. The detection and recommended treatment of micro-organisms which to some extent are part of the genital-tract microbiome, such as Mycoplasma hominis, Ureaplasma spp. or Gardnerella vaginalis, which do not cause symptoms in the majority of those infected, cannot be recommended. We argue that a shift from specialist-led to patient- and non-specialist-led STI management, in the presence of a clinical leadership vacuum, has increased the risk of inappropriate and unnecessary treatment which will drive macrolide, tetracycline and metronidazole antimicrobial resistance. However, in the past 5–6 years several groups have been able to show the value of on-line testing as a consequence of targeting the most important micro-organisms and using molecular tests to allow rapid and appropriately informed treatment. This should herald a brighter future, although there is still a need for leadership to expertly guide commercial and NHS sectors alike. In turn, this requires dedicated genito-urinary medicine commissioning to be maintained at a time when it appears to be most under threat.

show abstract

“…Appropriate targets could be missed by the software during the process, requiring manual intervention. 54 False-positive amplification due to hybridisation by primers is [192][193][194] (Continued) also common. 55 Hopefully, as the patent license (EP 1020534 B) for this technology expires in 2019, LAMP would experience more modifications.…”

Section: Loop-mediated Isothermal Amplification (Lamp)mentioning

confidence: 99%

Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections

Obande

Singh

2020

IDR

120

115

View full text Add to dashboard Cite

Nucleic acid amplification technology (NAAT) has assumed a critical position in disease diagnosis in recent times and contributed significantly to healthcare. Application of these methods has resulted in a more sensitive, accurate and rapid diagnosis of infectious diseases than older traditional methods like culture-based identification. NAAT such as the polymerase chain reaction (PCR) is widely applied but seldom available to resource-limited settings. Isothermal amplification (IA) methods provide a rapid, sensitive, specific, simpler and less expensive procedure for detecting nucleic acid from samples. However, not all of these IA techniques find regular applications in infectious diseases diagnosis. Disease diagnosis and treatment could be improved, and the rapidly increasing problem of antimicrobial resistance reduced, with improvement, adaptation, and application of isothermal amplification methods in clinical settings, especially in developing countries. This review centres on some isothermal techniques that have found documented applications in infectious diseases diagnosis, highlighting their principles, development, strengths, setbacks and imminent potentials for use at points of care.

show abstract

Detection ofChlamydia trachomatisandNeisseria gonorrhoeaewith the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Q^xand GC Q^xamplified DNA and Aptima AC2 assays

Abstract: The cobas CT/NG v2.0 test performs well using urogenital swabs, urine and cervical samples collected in PreservCyt solution.

Cited by 13 publications

References 14 publications

Genital and analChlamydia trachomatisbacterial load in concurrently infected women: a cross-sectional study

Genital and analChlamydia trachomatisbacterial load in concurrently infected women: a cross-sectional study

Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges

<p>Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections</p>

Contact Info

Product

Resources

About